Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyPalbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

The Journal of Clinical Oncology presents a Rapid Communications summary of the PENELOPE-B trial, a double-blind, placebo‐controlled, phase III study in women with HR+, HER2- primary breast cancer without a pathological complete response after taxane‐containing NACT and at high risk of relapse. With about one-third of women relapsing, palbociclib – a cyclin-dependent kinase 4 and 6 inhibitor – was examined.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form